@article{4073e721cef143d3808b8a246388273c,
title = "Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study",
abstract = "Introduction: We examined the associations among instrumental activities of daily living (IADL), cortical amyloid, and cognition in cognitively normal (CN) older adults. Methods: CN participants screening for the A4 Study (n = 4486) underwent florbetapir (amyloid) positron emission tomography. IADL were assessed using the Alzheimer's Disease Cooperative Study Activities of Daily Living Prevention Instrument. Separate logistic regression models were run with cortical amyloid or cognition as independent variable and IADL as dependent variable, adjusting for age and sex. Results: IADL difficulties were endorsed infrequently (≤16\%). Overall IADL and four select IADL item difficulties (“remembering appointments,” “finding belongings,” “following TV programs,” and “remembering current events”) reported by both participant and study partner were significantly associated with greater amyloid burden and worse cognition. Discussion: Although IADL deficits were infrequent in this CN cohort, greater participant and study partner report of overall IADL deficits and subtle difficulties in specific IADL items were associated with mildly higher amyloid burden and worse cognition.",
keywords = "Alzheimer's disease, amyloid, cognition, cognitively normal, florbetapir, instrumental activities of daily living, positron emission tomography",
author = "\{Full listing of A4 Study team and site personnel available at A4STUDY.org\} and Marshall, \{Gad A.\} and Sikkes, \{Sietske A. M.\} and Amariglio, \{Rebecca E.\} and Gatchel, \{Jennifer R.\} and Rentz, \{Dorene M.\} and Johnson, \{Keith A.\} and Oliver Langford and Chung-Kai Sun and Donohue, \{Michael C.\} and Rema Raman and Aisen, \{Paul S.\} and Sperling, \{Reisa A.\} and Galasko, \{Douglas R.\}",
note = "Funding Information: The A4 Study is a secondary prevention trial in preclinical Alzheimer's disease, aiming to slow cognitive decline associated with brain amyloid accumulation in clinically normal older individuals. The A4 Study is funded by a public-private-philanthropic partnership, including funding from the National Institutes of Health-National Institute on Aging (U19AG010483; R01AG063689), Eli Lilly and Company, Alzheimer's Association, Accelerating Medicines Partnership, GHR Foundation, an anonymous foundation and additional private donors, with in-kind support from Avid, Cogstate, Albert Einstein College of Medicine, US Against Alzheimer's disease, and Foundation for Neurologic Diseases. The companion observational Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) Study is funded by the Alzheimer's Association and GHR Foundation. The A4 and LEARN Studies are led by Dr. Reisa Sperling at Brigham and Women's Hospital, Harvard Medical School and Dr. Paul Aisen at the Alzheimer's Therapeutic Research Institute (ATRI), University of Southern California. The A4 and LEARN Studies are coordinated by ATRI at the University of Southern California, and the data are made available through the Laboratory for Neuro Imaging at the University of Southern California. The participants screening for the A4 Study provided permission to share their de-identified data to advance the quest to find a successful treatment for Alzheimer's disease. We would like to acknowledge the dedication of all the participants, the site personnel, and all of the partnership team members who continue to make the A4 and LEARN Studies possible. The complete A4 Study Team list is available at a4study.org/a4-study-team. Funding Information: Gad A. Marshall has received research salary support from Eisai Inc., Eli Lilly and Company, Janssen Alzheimer Immunotherapy, Novartis, and Genentech, and consulting fees from Grifols Shared Services North America, Inc.; Eisai Inc.; and Pfizer. Sietske A. M. Sikkes has received research support from Janssen, Axon Neuroscience, and Genentech and has received consulting fees from Boehringer and Toyama. Rebecca E. Amariglio has received research salary support from Eisai Inc., Eli Lilly and Company, and Biogen. Jennifer R. Gatchel has received research support from Merck. Dorene M. Rentz has received research salary support from Eli Lilly and Company and has received consulting fees from Eli Lilly, Neurotrack, and Lundbeck. Keith A. Johnson has received consulting fees from Novartis, Genentech, Biogen, AC Immune, Merck, Roche, Takeda, and Janssen. Oliver Langford reports no conflicts of interest. Chung‐Kai Sun reports no conflicts of interest. Michael C. Donohue has received research support from Eli Lilly and Company, Alzheimer's Association, and consulting fees from Eli Lilly and Company, Neurotrack, Biogen, and Roche. Rema Raman has received research salary support from Eli Lilly and Company and Janssen. Paul S. Aisen has received research support from Eisai Inc., Eli Lilly and Company, and Janssen, and has received consulting fees Biogen, Merck, Roche, Lundbeck, and ImmunoBrain Checkpoint. Reisa A. Sperling has received research support from Eli Lilly and Company and Janssen and has received consulting fees from AC Immune, Biogen, Eisai Inc., Janssen, Roche, and Takeda. Douglas R. Galasko has received research salary support from Eli Lilly and Company and Biogen, and consulting fees from vTv Pharmaceuticals, Cognition Therapeutics, and Fujirebio. Funding Information: The A4 Study is a secondary prevention trial in preclinical Alzheimer's disease, aiming to slow cognitive decline associated with brain amyloid accumulation in clinically normal older individuals. The A4 Study is funded by a public‐private‐philanthropic partnership, including funding from the National Institutes of Health‐National Institute on Aging (U19AG010483; R01AG063689), Eli Lilly and Company, Alzheimer's Association, Accelerating Medicines Partnership, GHR Foundation, an anonymous foundation and additional private donors, with in‐kind support from Avid, Cogstate, Albert Einstein College of Medicine, US Against Alzheimer's disease, and Foundation for Neurologic Diseases. The companion observational Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) Study is funded by the Alzheimer's Association and GHR Foundation. The A4 and LEARN Studies are led by Dr. Reisa Sperling at Brigham and Women's Hospital, Harvard Medical School and Dr. Paul Aisen at the Alzheimer's Therapeutic Research Institute (ATRI), University of Southern California. The A4 and LEARN Studies are coordinated by ATRI at the University of Southern California, and the data are made available through the Laboratory for Neuro Imaging at the University of Southern California. The participants screening for the A4 Study provided permission to share their de‐identified data to advance the quest to find a successful treatment for Alzheimer's disease. We would like to acknowledge the dedication of all the participants, the site personnel, and all of the partnership team members who continue to make the A4 and LEARN Studies possible. The complete A4 Study Team list is available at a4study.org/a4‐study‐team. Publisher Copyright: {\textcopyright} 2020 The Authors. Alzheimer's \& Dementia: Diagnosis, Assessment \& Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2020",
doi = "10.1002/dad2.12118",
language = "English",
volume = "12",
journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",
issn = "2352-8729",
publisher = "John Wiley and Sons Inc.",
number = "1",
}
SDG 3 Good Health and Well-being